LBX-100 is a clinical-stage drug candidate targeting glycine encephalopathy (nonketotic hyperglycinemia) to address metabolic dysfunction caused by glycine cleavage enzyme system defects.

LBX-200 is a clinical-stage drug candidate for treating urea cycle disorders by targeting enzyme or transporter defects involved in urea metabolism.